在霍奇金淋巴瘤VMAT优化中纳入心脏亚结构可降低心脏病风险
FaB-VMAT较B-VMAT显著降低全心脏、冠状动脉和左心室平均剂量及肺V20Gy,并降低冠心病和慢性心衰的相对风险;第二乳腺癌和肺癌风险总体相当,但纵隔大肿块女性患者B-VMAT乳腺剂量更低。
要点
- FaB-VMAT降低全心脏、冠状动脉和左心室平均剂量及肺V20Gy。
- FaB-VMAT显著降低冠心病和慢性心衰的相对风险。
- 纵隔大肿块女性患者B-VMAT乳腺剂量和终生归因风险更低。
核心结论
- FaB-VMAT较B-VMAT显著降低冠心病和慢性心衰的相对风险,肺和乳腺癌总体诱发风险几乎相同。
- 结果受不同解剖表现影响,支持个体化治疗策略。
研究设计与样本
- 病变范围包括纵隔加颈部10例、纵隔加单侧腋窝10例、仅纵隔10例。
- 将肺、乳腺、全心脏及亚结构(冠状动脉、瓣膜和心腔)勾画为危及器官并纳入优化过程。
- 比较第一代多弧蝴蝶VMAT(B-VMAT)与全弧蝴蝶VMAT(FaB-VMAT,由全弧加非共面弧组成)。
- 估算第二乳腺癌和肺癌的终生归因风险(LAR)以及冠心病(CAD)和慢性心力衰竭(CHF)的相对风险(RR)。
主要发现
- FaB-VMAT较B-VMAT降低全心脏平均剂量(7.6 vs 6.9 Gy,p=0.003)。
- FaB-VMAT较B-VMAT降低所有冠状动脉平均剂量(16.1 vs 13.5 Gy,p<0.001)。
- FaB-VMAT较B-VMAT降低左心室平均剂量(4.2 vs 3.4 Gy,p=0.007)。
- FaB-VMAT较B-VMAT降低肺V20Gy(15% vs 14%,p=0.008)。
- 纵隔大肿块女性患者中B-VMAT较FaB-VMAT降低乳腺平均剂量(2.8 vs 3.5 Gy,p=0.03)和V4Gy(22% vs 16%,p=0.04),并显著降低LAR(p=0.03)。
临床怎么用
- 对纵隔霍奇金淋巴瘤患者行VMAT优化时可将心脏亚结构纳入危及器官以降低冠心病和慢性心衰风险。
- 对纵隔大肿块女性患者需权衡乳腺剂量,B-VMAT在乳腺保护上可能更优。
- 应根据解剖表现个体化选择VMAT技术。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Radiotherapy is an effective treatment for Hodgkin's lymphoma (HL), but increases the risk of long term complications as cardiac events and second cancers. This study aimed to reduce the risk of cardiovascular events through an optimization of the dose distribution on heart substructures in mediastinal HL patients with the adoption of different volumetric modulated arc therapy (VMAT) techniques, while maintaining the same risk of second cancer induction on lungs and breasts. MATERIALS AND METHODS: Thirty patients (15 males and 15 females, 15 bulky lesions) treated between 2012 and 2017 at our institution were selected. Disease extent was mediastinum plus neck (n = 10), mediastinum plus unilateral axilla (n = 10) and mediastinum alone (n = 10). Lungs, breasts, whole heart and sub-structures (coronary arteries, valves and chambers) were contoured as organs at risk and included in the optimization process. A "first-generation" multi-arc butterfly VMAT (B-VMAT) planning solution was compared to a full-arc butterfly VMAT (FaB-VMAT) approach, consisting of a full arc plus a non-coplanar arc. Lifetime attributable risk (LAR) of second breast and lung cancer and relative risk (RR) of coronary artery disease (CAD) and chronic heart failure (CHF) were estimated. RESULTS: FaB-VMAT resulted in lower mean dose to whole heart (7.6 vs 6.9 Gy, p = 0.003), all coronary arteries (16.1 vs 13.5 Gy, p < 0.001), left ventricle (4.2 vs 3.4 Gy, p = 0.007) and in lower V20Gy to the lungs (15% vs 14%, p = 0.008). A significant lower RR for CAD and CHF was observed for FaB-VMAT. The risk of second breast and lung cancer was comparable between the two solutions, with the exception of female patients with mediastinal bulky involvement, where B-VMAT resulted in lower mean dose (2.8 vs 3.5 Gy, p = 0.03) and V4Gy (22% vs 16%, 0.04) to breasts, with a significant reduction in LAR (p = 0.03). CONCLUSIONS: FaB-VMAT significantly decreased the RR for CAD and CHF compared to B-VMAT, with almost the same overall risk of lung and breast cancer induction. These results are influenced by the different anatomical presentations, supporting the need for an individualized approach.
引用
- Levis M, Filippi AR, Fiandra C, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients. Radiother Oncol. 2019. PMID: 31146071. doi:10.1016/j.radonc.2019.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。